On March 25, officials at the Washington State Veterinary Office confirmed an 18-year-old Friesian mare at a King County boarding facility with equine herpesvirus myeloencephalopathy (EHM, the neurologic form of equine herpesvirus-1, or EHV-1). The mare had experienced onset of clinical signs, which included acute recumbency and hind-limb weakness, on March 19 and was euthanized due to the severity of her signs. Her vaccination status is not known.

Two other horses with fevers have been tested and will be monitored daily. The facility was quarantined and officials met with managers, boarders, and farriers to answer questions and outline biosecurity protocols.

EHV 101

Herpesvirus is highly contagious among horses and can cause a variety of ailments in equids, including rhinopneumonitis (a respiratory disease usually found in young horses), abortion in broodmares, and EHM.

In many horses, the first or only sign of EHV-1 infection is fever, which can go undetected. In addition to fever, other common signs of EHV-1 infection in young horses include cough, decreased appetite, depression, and a nasal discharge. Pregnant mares typically show no signs of infection before they abort, and abortions usually occur late in gestation (around eight months) but can be earlier. Abortions can occur anywhere from two weeks to several months following infection with EHV-1.

Horses with EHM usually have a fever at the onset of the disease and might show signs of a respiratory infection. A few days later, neurologic signs such as ataxia (incoordination), weakness or paralysis of the fore- and hind limbs, urine retention and dribbling, loss of tail tone, and recumbency (inability to rise) develop.

Herpesvirus is easily spread by nose-to-nose or close contact with an infectious horse; sharing contaminated equipment including bits, buckets, and towels; or clothing, hands, or equipment of people who have recently had contact with an infectious horse. Routine biosecurity measures, including hygiene and basic cleaning and disinfection practices, should be in place at all times to help prevent disease spread.

Current EHV-1 vaccines might reduce viral shedding but are not protective against the neurologic form of the disease. Implementing routine biosecurity practices is the best way to minimize viral spread, and the best method of disease control is disease prevention.